Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. (HNGE) is the issuer named in a Form 144 notice by 10% stockholder Insight Venture Partners (Cayman) X, L.P., which lists 399,338 Class A shares for sale through Raymond James & Associates, Inc. The approximate sale date is September 30, 2026; the listed aggregate market value is $39,135,124. The notice lists 62,468,721 shares outstanding.
Hinge Health, Inc. President James Pursley reported three sales of Class A Common Stock on September 21, 2026: 9,065 shares at a weighted average sale price of $93.3680 per share, 23,135 shares at a weighted average sale price of $94.4044 per share, and 800 shares at a weighted average sale price of $95.0968 per share. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026.
Hinge Health, Inc. (HNGE) has a notice under Rule 144 from officer James Pursley to sell up to 33,000 shares of common stock through Morgan Stanley Smith Barney LLC. The planned sale has an aggregate market value of $3,131,700 based on the price information provided.
The shares to be sold were acquired upon vesting of performance stock units between April 1, 2023 and March 31, 2025. The notice also lists prior 10b5-1 sales of 33,000 shares each in June and August 2026, reflecting ongoing liquidity transactions by this insider.
Hinge Health, Inc. (HNGE) director Robinson Elliott reported a sale of Class A Common Stock on September 14, 2026, carried out by affiliated Bessemer Venture Partners funds. Bessemer Venture Partners X L.P. sold 76,306 shares and Bessemer Venture Partners X Institutional L.P. sold 71,632 shares at a weighted average price of $93.53, in multiple trades between $92.71 and $93.64. Elliott has an indirect, passive economic interest through partnership interests in the Bessemer funds and disclaims beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 trading plan is reported.
Hinge Health, Inc. director and executive chairman Gabriel M.I. Mecklenburg reported converting 150,000 shares of Class B Common Stock into 150,000 shares of Class A Common Stock on September 14, 2026, and selling 150,000 Class A shares in multiple open-market transactions on the same date under a Rule 10b5-1 trading plan adopted on June 12, 2026. The sales occurred at weighted-average prices ranging from the high‑$80s to mid‑$90s per share. After these transactions, he held 1,844,004 Class B shares directly, plus additional Class B shares held indirectly through a family trust and a grantor retained annuity trust, each convertible into Class A on a one‑for‑one basis or as otherwise stated.
Hinge Health, Inc. (HNGE) director and executive chairman Gabriel M.I. Mecklenburg converted 250,000 shares of Class B Common Stock into Class A Common Stock on September 11, 2026, then sold 250,000 Class A shares in multiple open-market trades at weighted average prices within $86.35–$90.61. The sales were effected under a Rule 10b5-1 trading plan adopted on June 12, 2026. Following the conversion, he held 1,944,004 Class B shares directly and additional Class B shares indirectly through a family trust and a GRAT, representing 383,592 and 857,880 underlying Class A shares, respectively.
Hinge Health, Inc. (HNGE) reported that Chief Financial Officer James Budge sold a total of 55,561 shares of Class A common stock on September 10, 2026, in multiple open-market transactions at weighted average prices ranging from about $88.22 to $91.62. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by James Budge and his spouse on June 11, 2026.
Hinge Health, Inc. (HNGE) reported that CEO, co‑founder and major shareholder Daniel Antonio Perez and his spouse converted a total of 295,000 shares of Class B Common Stock into Class A Common Stock on September 10, 2026, then disposed of 250,000 Class A shares through open‑market sales and transferred 45,000 Class A shares as a bona fide gift. The sales were made under a Rule 10b5‑1 trading plan adopted on June 11, 2026, and Perez continued to hold 9,778,672 Class B shares directly and 208,445 Class B shares indirectly through his spouse after the reported conversions, excluding 3,777,002 performance‑based restricted stock units.
Hinge Health, Inc. (HNGE) reported that investment funds associated with director Robinson Elliott sold shares of its Class A Common Stock on September 9, 2026.
Bessemer Venture Partners X L.P. sold 5,489 shares and Bessemer Venture Partners X Institutional L.P. sold 5,848 shares at a weighted average price of $92.37, in multiple trades between $92.00 and $92.69. Elliott is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in these shares and disclaims beneficial ownership except to the extent of any pecuniary interest.
Hinge Health, Inc. (HNGE) received a notice under Rule 144 that Executive Chairman and Co‑Founder Gabriel Mecklenburg may sell up to 400,000 shares of common stock through Morgan Stanley Smith Barney. The notice ties these shares to prior Performance Stock Units and Restricted Stock Units and discloses that 83,334 shares of common stock were sold in the past three months under a 10b5-1 trading plan.